Polar Capital Funds PLC - Biotechnology Fund I Inc

Performance History31/01/2020
Growth of 1,000 (GBP) Advanced Graph
Polar Capital Funds PLC - Biotechnology Fund I Inc
Fund10.319.52.126.2-6.0
+/-Cat14.29.210.16.0-3.2
+/-B’mrk16.58.45.35.9-0.9
 
Key Stats
NAV
21/02/2020
 USD 28.31
Day Change -1.17%
Morningstar Category™ Sector Equity Biotechnology
ISIN IE00B42Z4531
Fund Size (Mil)
14/02/2020
 USD 565.95
Share Class Size (Mil)
20/02/2020
 USD 357.10
Max Initial Charge 5.00%
Ongoing Charge
18/02/2020
  1.17%
Investment Objective: Polar Capital Funds PLC - Biotechnology Fund I Inc
The investment objective of the Fund is to preserve capital and achieve long term capital appreciation.
Returns
Trailing Returns (GBP)21/02/2020
YTD3.80
3 Years Annualised12.13
5 Years Annualised13.55
10 Years Annualised-
12 Month Yield 0.00
Dividend Paying Frequency Annually
Management
Manager Name
Start Date
David Pinniger
31/10/2013
Inception Date
31/10/2013
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDNASDAQ Biotechnology TR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNo
GrowthYes
IncomeNo
HedgingNo
OtherNot Specific
Portfolio Profile for  Polar Capital Funds PLC - Biotechnology Fund I Inc30/11/2019
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock96.660.0096.66
Bond0.000.000.00
Property0.000.000.00
Cash3.340.003.34
Other0.000.000.00
Top 5 Regions%
United States72.04
Eurozone12.72
Europe - ex Euro8.24
United Kingdom4.33
Canada2.67
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Alexion Pharmaceuticals IncHealthcareHealthcare6.11
Incyte CorpHealthcareHealthcare6.06
argenx SEHealthcareHealthcare5.85
Seattle Genetics IncHealthcareHealthcare5.38
NanoString Technologies IncHealthcareHealthcare4.09
Polar Capital Funds PLC - Biotechnology Fund I Inc

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites